Renegeron (NASDAQ: REGN) announced the European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Regeneron (REGN) Tops Q2 EPS by 61c, Revenues BeatAugust 6, 2019 6:43 AM Regeneron (REGN) Highlights Positive Topline Results in Phase 3 TrialAugust 6, 2019 5:48 AM Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis August 6, 2019 1:01 AM